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 Between 2000 and 2012, the national rate of Neonatal Abstinence Syndrome (NAS) has 
increased over 400 percent, from 1.2 to 5.8 per 1,000 live births.1 A region hard-hit by the opioid 
epidemic, some Appalachian counties in East Tennessee report NAS rates more than 10 times the 
national average, “with rates exceeding 60 per 1,000 live births.”2 Knox County’s NAS incidence 
peaked in 2014, at 22.6 per 1,000 live births and has since held steady at just over 20 per 1,000 
live births. 3 As concern over the opioid epidemic increases, so have community efforts to *
combat it. As evidenced by the opioid epidemic, drug use pervades race, socioeconomic status, 
geography, and age; even neonates are not immune to drug addiction.  
 Dr. Loretta Finnegan first described Neonatal Abstinence Syndrome in the 1970’s. She 
developed the first scoring system for babies who exhibited symptoms of withdrawal after birth 
to provide a more objective evaluation of the infant’s withdrawal status. Providers still use the 
Finnegan scoring system today before, during, and after treatment to monitor progress and adjust 
pharmacologic treatment according to its uniform criteria. The Finnegan system assigns scores to 
specific symptoms in an itemized list that include central nervous system disturbances such as 
high pitched cry and tremors, metabolic and respiratory disturbances including hyperthermia, 
and gastrointestinal disturbances like poor feeding and regurgitation. NAS symptoms and criteria 
are listed in Table 1.4,5 Providers initially attempt to treat these symptoms with non-
pharmacological such as breast-feeding, low-stimulus environments, and swaddling. If these 
interventions do not sufficiently manage symptoms, then providers  
 Most recent annual report available is for 2017*
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use pharmacological treatments such as diluted morphine tinctures and phenobarbital. Research 
has shown prolonged exposure to opiates poses adverse neural, cognitive, and behavioral 
outcomes in the developing brain. Investigating how we can minimize pharmacotherapy 
treatment when possible, and promote favorable developmental outcomes is of great importance 
as hospitals see increased numbers of NAS patients. 
 While the health outcomes of babies in the Neonatal Intensive Care Unit (NICU) prove 
more than important finances, the financial strain on both families and healthcare systems due to 
increased length of stay should not be ignored. Since building a new NICU wing in 2012 
specifically for neonates born with NAS, East Tennessee Children’s Hospital (ETCH) spent over 
seventy five million dollars to expand it to sixty six private rooms. Babies born with NAS 
“experience withdrawal just like adults,” ETCH writes on their site, describing the new NICU 
wing. “They have a screech-like cry, claw their faces, and squirm.” This wing is built to limit 
stimulation; it has dark lighting, quiet rooms, and special volunteers to comfort the babies.6 In a 
Table 1. Neonatal Abstinence 
Syndrome Symptomology.4,5
Central Nervous System 
Disturbances
Metabolic, Vasomotor, and 
Respiratory Disturbances
Gastrointestinal Disturbances
High pitched crying Sweating Excessive sucking
Sleep disturbances Frequent yawning Poor feeding
Myoclonic jerks Mottling Regurgitation
Hyperactive Moro reflex Nasal stuffiness Projectile vomiting
Tremors Sneezing Loose or watery stools
Increased muscle tone Nasal flaring Weight Loss
Excoriation Increased respiratory rate ( > 60/
min), with or without retractions
Convulsions/seizures Hyperthermia
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similar attempt to create a less stimulating environment, the University of Tennessee Medical 
Center (UTMC) has a NICU wing for NAS babies with a noise level of about 25-30 decibels, 
much lower than the noise levels in the open bay, which range from 80-100 decibels. Less than 
two miles from ETCH, UTMC has also expanded its NICU in recent years to accommodate 
increasing numbers of NAS patients. Just this year, at the end of March, UTMC opened “The 
Firefly Cove” to accommodate NAS babies; the previously described, $60 million, new 30-bed 
NICU wing. Last year, UTMC admitted 860 babies, and for the past ten years or so, babies with 
NAS account for roughly 20 percent of NICU admissions.7 In 2009, hospital charges for NAS 
patients’ course of treatment averaged over $50,000.8 
Prematurity and in-utero drug exposure 
 One study of preterm drug-exposed infants shows these infants frequently exhibit lower 
Finnegan scores than term infants do on several criteria, suggesting the need for an NAS scoring 
system specific for preterm infants’ symptomology.9 Despite consistent drug exposure during 
gestation, preterm infants develop NAS less often than term infants. This difference could be 
attributed to the NAS scoring system, which is symptom-based and is not optimized for preterm 
infants; or possibly because preterm infants lack a more developed CNS.10 Premature infants, 
however, are born during a critical window of gestation – a period of rapid brain development. 
Dr. Allocco writes that “the combination of preterm birth and in-utero opioid exposure puts the 
infant at particularly high risk for poor neurodevelopmental outcomes.” Currently, no 
standardized treatment guidelines exist for preterm drug-exposed neonates. Although these 
babies do not experience withdrawal in the same way, this does not necessarily indicate 
decreased severity of NAS.11 The experience of in-utero drug exposure lays the foundation for 
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these infants’ neurodevelopment, even if not apparent in the first few days of life. Premature 
neonates are rarely studied in the context of NAS. NAS scoring requirements would exclude 
nearly all of these patients from the study. The inclusion of drug-exposed premature neonates 
allows us to examine what developmental impact, if any, that in-utero drug exposure has on these 
infants’ development.  
The role of proprioceptive input 
 Integration of sensory input allows the sensory systems like vestibular, proprioceptive, 
and tactile systems to guide the body’s movement.12 Proprioceptors tell the body its location in 
space relative to environmental features and the body itself. Kathleen Cullen writes: “The ability 
to distinguish self-generated sensory events from those that arise externally is … essential for 
perceptual stability and accurate motor control.”13 Proprioception plays two critical roles in 
motor control. One function of proprioception is that it provides the quickest and most accurate 
input with respect to detecting unexpected changes in the external environment that necessitate 
alteration in movement. Secondly, proprioception provides periodic information about movement 
and position during motor movements. This input influences “planning and modification of 
internally generated motor commands.”14 Adequate functioning of proprioceptors is necessary 
for locomotion, and proprioceptive exercises that strengthen neural connections can aid in 
development of these motor control systems.  
 Over the past twenty or so years, Dr. Miriam Weinstein has implemented proprioceptive 
cross-stroking exercises in the UTMC NICU to aid in neurodevelopment. In the plastic neonate 
brain, proprioceptive input can have maximal impact. This technique can be taught to and 
utilized by nurses and caregivers, so babies can receive this treatment both in and out of clinical 
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settings. This paper presents a universally-available neurodevelopmental treatment for at-risk 
neonates. The data used in this study comes from a larger ongoing study led by Dr. Weinstein, a 
pediatric physiatrist at the University of Tennessee Medical Center (UTMC) in Knoxville, 
Tennessee. The patients in this study were all seen by Dr. Weinstein in the UTMC NICU, and all 
received the cross-stroking exercise intervention. 
 This study initially began researching the impact of these exercises on motor 
development. Upon data analysis, intriguing differences in length of stay became apparent. We 
discuss how the intervention has played a role in the early postnatal stage and its implications for 
later in development. NAS’ potential indication for proprioceptive cross stroking exercises is 
promising. We describe the role of proprioception in two of the three clusters of NAS symptoms, 
Central Nervous System (CNS) and respiratory disturbances. 
Methods 
 Dr. Weinstein, a pediatric physiatrist (PM&R), implemented cross stroking (CS) exercises 
during rounds in the University of Tennessee Medical Center’s Level III NICU. Nurses 
performed CS by gently holding the infant’s right hand to the left cheek, then with the back of 
the right hand, stroke down the left arm all the way to the fingertips. Then the left hand repeated 
this same exercise. Nurses repeated this sequence on each side three times before bringing one 
hand to rest on top of the other on the chest. In addition to having sensorimotor and segmental 
spinal cord components, this exercise gives afferent proprioceptive input to the motor cortex. 
This free and simple hands-on technique taught to all nurses did not place undue burden on them 
in the busy NICU. Besides creating an instructional video, this intervention was implemented 
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with no extra equipment. Families and caregivers were also taught the intervention to encourage 
involvement and maximize opportunity for the neonates to receive the exercises. Because the 
NICU is very busy, the intervention’s simplicity and minimal demand of nurses’ time was of 
great importance. Other therapists who rounded once a week also performed the exercises. 
Following NICU discharge, PM&R monitored these patients, instructed mothers on CS and other 
exercises, and coordinated care with therapists.  
 For this study, I reviewed all of the charts in Dr. Weinstein’s office for patients that were 
exposed to drugs in-utero. These patients were divided into two categories, NAS and Drug-
Exposed Premature. This study categorizes prematurity as infants born at 32 weeks’ gestational 
age or less. Inclusion criteria eliminated some patients from the study whose charts were 
originally included. UTMC uses the Finnegan scoring system to diagnose NAS. If the patients 
did not have a diagnosis of “NAS” on their NICU summary, “in utero poly-substance exposure” 
had to be listed as a diagnosis for inclusion; in order to analyze effects of drug-exposure in 
premature patients, this was particularly important for inclusion.  For the patients who had in-*
utero poly-substance exposure, some were not included in the study because they were not 
clearly affected by the exposure; babies excluded from the study who had “in-utero poly-
substance exposure” were AGA/normal-to-high birth weight, had high Apgar scores, spent 
limited time in the NICU (<10 days), or only admitted to the NICU for reasons unrelated to drug 
exposure. “In utero drug exposure” or “poly substance exposure” is characterized by 1) 
consistent drug use self-reported by mother during pregnancy, and supported by positive urine or  
 Premature infants are rarely diagnosed with NAS, see References: 9*
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other samples, when available 2) neonate with positive meconium or urine sample. Another 
inclusion factor required patients stay in Dr. Weinstein’s practice after discharge from the NICU, 
for at least one year or until they reached developmental milestones, such as cruising and 
walking (whichever occurred earliest.) Table 2 shows demographics of patients in the study.  *
 This study uses walking age as a measurement of development because it serves as an 
important motor milestone and convenient identifier of development: Dr. Weinstein frequently 
recorded walking ages in patient charts that were not initially intended for research. “Walking” is 
defined as taking six or more steps independently. Because of the manner which the data was 
recorded, gaps exist in available data for each patient. Of the twelve patients in the Drug-
Table 2. Patient demographics. Drug-Exposed Premature NAS
n                               Mean ± SD n                               Mean ± SD
N 12 36
Gestational age (weeks) 12                             28 3/7 ± 1.9 35                            37 4/7 ± 2.4
Birth weight (grams) 12                        1121.3 ± 301.9 36                              2697 ± 532
1-minute Apgar score (points) 12                                  4.2 ± 2.2 35                                  7.8 ± 1.1
5-minute Apgar score (points) 12                                  6.6 ± 1.5 35                                  8.7 ± 0.9
SGA (small for gest. age) 1 (8.3%) 9 (25%)
AGA (average for gest. age) 12 (91.7%) 27 (75%)
IUGR 1 (8.3%) 6 (16.7%)
NICU LOS (days) 12                              97.8 ± 38.6 34                            20.91 ± 9.69
Walking age (months) 8                              18.09 ± 4.17 23                              11.7 ± 1.72
Received PT 11 (91.7%) 13 (36.1%)
Received OT 8 (66.7%) 10 (27.8%)
Received Orthodics 3 (25%) 5 (13.9%) 
 table excludes outliers, explained in results*
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Exposed Premature category, one left the practice before acquiring ambulation and one other had 
inconclusive data in the file about their walking age. Of the thirty six NAS patients, two left the 
practice before acquiring ambulation, and nine had inconclusive data about walking age 
described in their charts.  In most cases walking ages were well documented, with office notes *
that corroborated parent reports; some charts had a lapse of visits and in which, parent reports 
were the only certain evidence of at the exact age a patient first walked independently. 
Altogether, definitive walking ages have been established for 34 patients, 9 in Drug-Exposed 
Premature and 25 from NAS. The length of stay in the NICU was determined for all but two 
patients, one in each category. All data was obtained from patient charts. No identifying 
information was recorded in data sets. 
 An interdisciplinary approach to medical treatments proves beneficial to patient 
outcomes. Proprioceptive cross stroking constitutes just one of the interventions for NAS 
treatment. Because of Knoxville’s unique geographical relation to the opioid epidemic, we also 
examined some of the social history of the patients, such as type of drug exposure and post-
discharge placement. This information is valuable when assessing developmental interventions in 
the context of gestational drug use, maternal and prenatal care, and NAS treatment. 
Results  
 The average gestational age of the NAS neonates was 37 weeks and 4 days (SD=2.4 
days). The average birth weight for NAS was 2697 grams ± 532 grams; seventeen of the thirty-
six neonates delivered were Low Birth Weight (LBW < 2500g). Drug-Exposed Premature’s 
 Inconclusiveness can be attributed to gaps in visits that overlapped the age at which they *
began walking, or ambiguous notation in files from which a definitive walking age could not be 
established
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average gestational age was 28 weeks and 3 days (SD=1.9 days). The average birth weight for 
Drug-Exposed Premature was 1121.3 grams (SD=301.9 g). With the exception of one, all of the 
Drug-Exposed Premature patients were classified Very Low Birth Weight (VLBW < 1500g).  *
Twenty nine of the NAS patients were formally diagnosed with NAS.  Only one of the twelve †
Drug-Exposed Premature patients was diagnosed with NAS. Six of the 36 NAS patients suffered 
intrauterine growth restriction while again, only 1 of the 12 Drug-Exposed Premature patients 
did. Twenty seven (75 percent) of NAS patients received pharmacologic treatment, and eight 
(22.2 percent) did not receive pharmacologic treatment.  The difference in percentage of Small ‡
for Gestational Age (SGA) births between non-premature and premature categories, 25 percent 
vs. 8 percent, suggests a lesser effect of gestational drug-use in premature neonates.   
Drug Use 
 Between 60 and 80 percent of newborns exposed to heroin or methadone in utero show 
NAS symptoms.15 While Neonatal Abstinence Syndrome presents most frequently in the context 
of gestational opiate use, other drugs are also of concern.16-18 Figure 1 shows antepartum drug 
use by mothers of patients in the study. Many mothers used several drugs concurrently; 
percentages are not mutually exclusive.  
 Of the 48 moms of babies in the study, 41 used narcotic pain relievers (including illicit 
drugs, opiates/opioids, and opiate replacements.) The seven who did not use narcotic pain 
relievers during pregnancy used at least one of the following drug types: benzodiazepines, 
 The one VLBW exception was LBW*
 Inclusion of non-NAS patients in NAS is explained in Length of Stay — NAS results†
 One chart of patient (diagnosed as NAS) was missing a NICU summary so whether they ‡
received pharmacologic intervention is inconclusive
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barbiturates, sedative-hypnotics, anxiolytics, amphetamines, or stimulants. Though tobacco does 
not cause Neonatal Abstinence Syndrome, it mediates increased NAS peak scores, and impacts 
the timing of the course of NAS, when used in conjunction with methadone.19 Roughly 91 
percent of mothers of babies in this study used tobacco or nicotine patches regularly. Forty seven 
percent used marijuana during pregnancy. Studies have shown mixed outcomes of gestational 
marijuana exposure, with no certain fetal abnormalities; some long-term behavioral and 
emotional outcomes have been described, but no major withdrawal symptoms have been 
observed.20 
 From this data, we also found that opioid replacement medication use was not the 
strongest predictor of whether moms used other opiates/opioids. Antidepressant use was most 
highly correlated with no maternal opiate use. Of the nine women using antepartum 
antidepressants, only one used opiates/opioids; this woman did not use opiate replacement 
medication. Twenty seven of the women in the study used opiates or opioid medications with no 
opiate replacement treatment. Fourteen of the mothers used antepartum opiate replacement 
medications, half of whom used in conjunction with opiate/opioid drugs. Figures 2 and 3 show 
proportions of antepartum drug use compared with use of narcotic pain relievers. 
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Walking Age 
 Distribution of the age that patients began walking independently shown in Figure 4 ; *
Drug-Exposed Premature (left), NAS (right.) Tables 3 and 4 show summaries of Drug-Exposed 
Premature and NAS data, respectively.  
 Outliers removed*
Figure 2 (top). 
Antepartum drugs vs 
opiates/opioid use.
Figure 3 (bottom). 
Antepartum drugs vs 
opioid replacement use.
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Drug-Exposed Premature  
 For Drug-Exposed Premature, [n=8] the mean walking age is 18.1 months ± 4.2. The 
median walking age is 17.5 months, with lower and upper quartiles being 14.5 and 20.5. One 
major outlier (x=54) was excluded from the Drug-Exposed Premature data. After the removal of 
the 54 months outlier, another data point (x=26 months) became a minor outlier. For 
consistency’s sake, and because of the extremely small sample size, this outlier was left included 





































Figure 4. Distribution of walking age (months). Drug-Exposed Premature shown 
left. NAS shown right.
Table 4. NAS walking age (months) 
[n=23]
Mean = 11.7 ± 1.7 (SE=0.3) 
95% Mean CI [11, 12.4]  
95% SD CI [1.3, 2.4]
Median = 11 (IQR=2.5)
Table 3. Drug-Exposed Premature 
walking age (months) [n=8]
Mean = 18.1 ± 4.2 (SE=1.5) 
95% Mean CI [14.6, 21.6]  
95% SD CI [2.8, 8.5]
Median = 17.5 (IQR=6)
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months ± 2.89. The age at which these patients acquired independent ambulation exceeds the age 
for typical children but this can be attributed to compounded adverse conditions of birth and 
development. No developmental studies exist to which we can compare these patients. All but 
one of these patients received extra therapies (physical therapy, occupational therapy, orthotic 
devices) beyond the cross-stroking exercises and at-home exercises assigned by Dr. Weinstein.  
NAS   
 The mean walking age of NAS patients [n=23] is 11.7 months ± 1.72, 95% Mean CI 
[10.95, 12.44]. The median walking age for NAS is 11 months, with the lower and upper quartile 
values being 10.5 and 13 months, respectively. We determined definitive walking ages for 25 
patients but for this data set, two outliers were excluded, 18.5 months and 23.5 months. Before 
the data point with the value 23.5 was removed, the 18.5 month data point was only a minor 
outlier; after removal of 23.5 however, 18.5 months became a major outlier as well, so it was 
also removed. Receiving other therapies did not affect the age at which infants acquired 
independent ambulation (Table 5). Neonates discharged to their mothers showed greater 
compliance compared to those discharged to 
other family members or foster families.  *
Other patients less frequently had exact 
walking ages recorded in their charts, which 
indicate that they missed appointments more 
frequently or had large gaps in treatment 
during critical periods of development. Of the 
 This includes patients discharged to mothers under the supervision of other family members*




Mean walking age 
(months) = 11.6875 

SD = 1.41, SE=0.5

95% Mean CI [10.51, 
12.86]
Did not receive other 
therapy treatments* 
[n=14]





95% Mean CI [10.64, 
12.76]
*PT, OT, orthotic 
devices
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twenty-three patients included in the walking data, fourteen patients were discharged from the 
NICU to their mothers, grandparents, or other family (occasionally through foster care.) Nine 
NAS patients were placed in foster care with non-family members upon discharge. These nine 
patients began independently walking slightly later, at 12 ± 1.3 months, than their family-placed 
counterparts who walked at 11.2 ± 1.6 months.  
Length of Stay (LOS) 
Drug-Exposed Premature  
The average LOS for our Drug-Exposed 
Premature patients is 99.3 ± 40.2 days, 95% 
Mean CI [72.3, 126.3]. The median LOS is 100 
days with the IQR parameters being 70 and 
123. Length of stay for Drug-Exposed 
Premature patients was not correlated with 
birth weight. Drug-exposed premature Apgar 
scores for 1- and 5-minutes averaged 4 ± 2, and 
6.5 ± 1.5, respectively. Figure 5 shows the LOS 
distribution and Table 6 shows corresponding 











Figure 5. Length of stay (days) for 
Drug-Exposed Premature.
Table 6. Length of Stay (Days) for Drug-
Exposed Premature [n=11]
Mean = 99.3 ± 40.2 (SE=12.1) 
95% Mean CI [72.3, 126.3]  
95% SD CI [28.1, 70.5]
Median = 100 (IQR=53)
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NAS 
 Data was only available for 34 of the 36 NAS patients due to NICU summaries missing in 
two of the charts. Distribution shown in Figure 6, and summary statistics in Table 7. Neonates 
stayed in the NICU, on average, for 20.9 days ± 9.4. The median LOS was 21 days, with the 
upper and lower interquartile values being 12 and 28 days, respectively.  Birth weight did not 
significantly influence LOS; LBW neonates and non-LBW neonates average length of stays were 
20.6 and 21.2, respectively. Twenty-nine of the patients in this category were diagnosed as 












Figure 7. LOS of NAS patients 











Table 8. Length of Stay (Days) of all 
NAS patients diagnosed NAS [n=27]
Mean = 21 ± 9.4 (SE=1.8) 
95% Mean CI [17.3, 24.7]  
95% SD CI [7.4, 12.8]
Median = 21 (IQR=16)
Table 7. Length of Stay (Days) of all 
NAS patients [n=34] 
Mean = 20.9 ± 9.7 (SE=1.7) 
95% Mean CI [17.5, 24.3]  
95% SD CI [7.8, 12.8]
Median = 21 (IQR=16)
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“NAS.” Only one patient who was diagnosed as NAS did not receive pharmacologic treatment; 
this patient stayed in the NICU for only 5 days - the shortest length of stay of all patients in the 
study.  Seven of the thirty six patients in the NAS category were not diagnosed NAS in the *
NICU, but were diagnosed with “in-utero poly substance exposure” and included in the study. 
Figure 7 shows distribution of the patients in the study who did receive NAS diagnosis; summary 
statistics shown in Table 8. These patients’ average length of stay was 21 days ± 9.7. The length 
of stay for patients who did receive NAS diagnosis was not significantly different than from the 
whole of patients in the category. For patients that did not receive NAS diagnosis, the average 
LOS was 20.6 days ± 11.7. There was only one patient who did receive NAS diagnosis that did 
not receive pharmacological treatment. Creating a sample of all patients who were diagnosed as 
NAS and received pharmacologic treatment involves removal of only a single data point, and 
thus, had negligible impact on the LOS. 
Discussion 
 The Drug-Exposed Premature category is a very small sample size of all drug-exposed 
premature neonates. These statistics should be interpreted as insights into the condition of drug 
exposed neonates, rather than statistics that are descriptive of all drug-exposed neonates. The 
differences between drug-exposed premature patients and non-drug-exposed premature patients 
highlights the need for continued research of this patient population.  
 The two patients whose NICU summaries I could not find (thus, LOS = unknown) were both *
diagnosed NAS
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Drug use 
 Because the sample size is extremely small, further studies should assess the validity of 
the claim that antidepressant use is correlated with less opiate use.  Another possible explanation *
for this correlation is that a therapeutic regimen for depression may indicate better access to 
medical professionals, and these women are more likely to be using replacement therapy than 
illicitly using drugs. Additional evidence supporting this possibility is that women who took 
antidepressants while pregnant were much more likely to use benzodiazepines - indicating they 
potentially received psychiatric treatment. Lapses in documentation of the medication/drug 
sources pose limitations to this study; it is possible that women using opiate replacement 
medications obtained them illicitly, used them unmonitored by providers, or abused them by 
using them at unprescribed frequencies or dosages. Meanwhile, some women claimed they used 
prescription pain relievers, but prescriptions were not always confirmed.  
Walking Age 
Drug-Exposed Premature 
 All but one of the patients in our study received other therapies, including physical 
therapy, occupational therapy, and orthotic devices. Even after receiving these therapies and the 
cross-stroking exercises, these patients began walking independently at around 18 months. When 
for controlling for gestational age, studies have shown that premature infants attain independent 
ambulation at a later age than term infants. Our patients independently walked later than other 
premature infants. Drug-Exposed Premature patients walked much later (M=18.1 months, 
SD=4.2) than the non-premature NAS patients (M=11.7, SD=1.72.) The Apgar scores for our 
 n(women who used antidepressants) = 9*
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patients (1-Minute M=4.2, 5-Minute M=6.6) averaged about two points lower than Apgar scores 
for other premature patients.21 These lower Apgar scores support the theory that effects of 
prematurity and drug-exposure likely compound to result in greater adverse outcomes.  
NAS 
 The NAS group’s walking age (M=11.7 months, SD=1.72.) is typical for children, with 
documented average age being around 12 months.22 Limited research exists on NAS’ long-term 
developmental impact, but data from this study shows these babies reach the “walking 
independently” motor milestone slightly before the average. These “slightly before the average” 
ages can most likely be attributed to a smaller sample size, as well as the fact that these children 
received the cross-stroking therapy both in the NICU and at home, as well as at-home exercise 
plans Dr. Weinstein gave. The thirteen patients  discharged from the NICU to family members *
(including mothers) walked earlier (M=11.2 months, SD=1.6) than the nine patients placed with 
non-family foster care (M=12 months, SD=1.3). This difference is small, but likely attributed to 
family members being more familiar with the condition of the patient and exercise plans than 
foster parents. Patients discharged to non-familial foster care had more gaps in treatment than 
those discharged to family. Foster parents were instructed on the exercises before discharge but 
family who spent more time in the NICU with the patients likely performed the exercises more 
frequently and were more familiar with them post-discharge. 
 NICU discharged fourteen patients with family, but one outlier (15.5 months) was excluded *
from this data set
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Length of Stay 
Drug-Exposed Premature 
 The length of stay in the Drug-Exposed Premature category did not shorten; in fact, the 
length of stay for these patients was longer than the average premature neonates’ stay. One study 
of thousands of newborns’ NICU stays found the neonates born at 28 weeks’ gestation resided in 
the NICU for 66 days on average; for 30 weeks the stay averaged 48 days.23 There is very little 
data on NAS and prematurity but our data suggests that drug exposure necessitates a much 
longer stay than for non-exposed premature neonates. Because the Finnegan scoring system is 
symptom-based, many drug-exposed premature neonates may not qualify for an NAS diagnosis, 
and thus elude NAS care. This lapse in treatment could explain longer NICU stays for these 
patients. Though limited (N=12), this data indicates a need for greater research on the impact of 
in-utero drug exposure in the context of prematurity. 
NAS 
 The similar lengths of stay between NAS and non-NAS neonates justifies the inclusion of 
these neonates who were drug-exposed but not formally diagnosed as NAS in the study. Non-
NAS neonates in the NAS category stayed in the NICU an inappreciably less length of time; one 
that is not statistically significant. This suggests a discrepancy in diagnoses rather than actual 
conditions of the infant, likely caused by providers coding diagnoses differently and non-uniform 
Finnegan scoring usage. This inclusion does not, however, extend to all drug-exposed neonates. 
Including these patients shows disparities in diagnosis and treatment of NAS. Rather than assert 
drug exposure warrants NAS diagnosis, this data demonstrates the possibility that not all 
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neonates are evaluated in the same fashion. Of course there are always exceptional cases; the one 
patient who was diagnosed NAS and did not receive pharmacologic treatment was sent home 
after just 5 days. 
 Proprioceptive cross-stroking points to decreased length of stay for babies with NAS 
cases that warranted NICU stay. Though we have not explored what symptomology has been 
specifically impacted by proprioceptio, we have identified proprioception’s role in two of the 
three main foci of NAS pathology, the CNS and respiratory disturbances. Both hospitals and 
families have a vested interested in reducing length of stay; longer length of stay places both 
under financial strain, and also results in psychosocial strain on families and patients. One 2003 
study found the average length of stay for NAS neonates to be 30 days.24 Another study 
comparing pharmacologic treatments found the average length of stay of neonates treated with 
the most effective pharmacologic combination in the study to be 38 days.25 Before a years-long 
NICU LOS reduction effort by a multidisciplinary task-force in Ohio, the NICU LOS in the 
hospital system for NAS neonates averaged 36 days.26 A study comparing LOS associated with 
treatment by methadone and an oral morphine preparation found the average length of stays to be 
40 and 36 days, respectively.27 
Why the shorter length of stay? 
 The shorter LOS seen in NAS patients who received cross-stroking exercises could be 
attributed to the plasticity in the young neonate brain; providers and caregivers can utilize this 
plasticity to regulate CNS functioning in vulnerable neonates. Neonates, just as adults, 
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experience increased pain sensitivity and an exaggerated pain response during opiate withdrawal. 
The CNS processes afferent input received from proprioceptors.28  
 Interventions can reduce pain directly “by blocking nociceptive transduction or 
transmission or by activation of descending inhibitory pathways…” Opioids are the staple for 
pharmacotherapy for direct pain management in neonates, but these drugs can have adverse 
developmental effects.29,30 Indirect non-pharmacological means of reducing pain in neonates 
include environmental measures, breastfeeding, and skin-to-skin contact.31  
 One animal study of acute opiate withdrawal shows evidence of neonatal rats 
experiencing allodynia  and hyperalgesia in this context.32 In neonates, this confusion in afferent *
input is in part due to the plasticity of the brain. Peripheral proprioceptive neurons converge onto 
central nociceptive neurons in the dorsal horn, where they have the opportunity to activate 
nociceptors. In adults with normal afferent activity, and with no nerve or tissue damage, the 
synaptic locales of the neurons is inconsequential. Neural plasticity, however, can sensitize 
nociceptors to the proprioceptors’ activity, which causes the neonate to perceive normal 
proprioceptive input as painful. Just as pain can be “learned” through neural plasticity, it can be 
unlearned through regular afferent input.33,34 The early postnatal stage is critical for neural 
plasticity, specifically, dorsal horn plasticity.35 Proprioceptive cross-stroking provides consistent 
peripheral afferent input that can mediate the fine-tuning of these connections in the dorsal horn.
36,37 In the short-term, could aid the neonate in self-regulatory soothing. In the long-term, this 
could help correct the maturation process of afferent input innervation. Proprioceptive input 
 Allodynia is a conditioned in which a normal, non-painful stimulus, such as clothes touching *
the skin, causes an abnormal or painful sensation)
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reduces length of stay by promoting CNS development and fine-tuning the CNS response to 
allodynia secondary to drug-withdrawal.38 
 Repetitive pain exposure can cause permanent changes to the immature pain system of 
the neonate.39 Early repetitive pain exposure contributes to altered pain thresholds and 
physiological responses, as well as adverse neurodevelopmental outcomes.40-42 All potential 
ways to reduce the risk of these unfavorable outcomes should be evaluated. 
 Drug-exposed neonates often have signs of respiratory disturbances including increased 
respiratory rate, transient tachypnea, chest retractions, and nasal flaring. NAS patients frequently 
require cardiopulmonary assistance such as supplemental oxygen, ventilation, and intubation.43 
One study has shown that proprioceptive limb stimulation in premature neonates has reduced the 
number of breathing pauses and intermittent hypoxia. Proprioceptive interventions can increase 
breathing and synchronize breathing patterns with limb movement. Neuromodulation of 
proprioceptive afferents offers a non-invasive and low-cost method to reduce aberrant breathing 
episodes; these interventions promote neural and pulmonary development, rather than reliance on 
mechanical and pharmacologic agents, which pose risks to the development of these structures.44  
Limitations and further research 
 Many length of stay studies disproportionately exclude many of the patients that 
inevitably have longer NICU stays. Some studies show NAS neonates with a shorter average 
NICU stay than our patients. A quarter of the NICU sites in paper that published results from a 
years-long task force were Level II NICUs; this study also excluded patients born <35 weeks’ 
gestation.45 UTMC’s Level III NICU is equipped to handle more severe NAS cases; neonatal 
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teams at other hospitals in the area care for drug-dependent neonates who do not have severe 
enough symptoms to warrant NICU admission.49 Another study with a shorter LOS than our 
paper excluded “not otherwise well newborns” and those born less than 35 weeks’ gestation. It 
also included NAS patients who were placed in the pediatric unit; thus, it included many patients 
who exhibited less severe NAS cases.46 The newborns in our study all resided in the NICU 
before the hospital created major initiatives to optimize the NICU environment for these babies. 
Other studies with similar shorter lengths of stay have excluded with mothers who engage in 
poly-drug uses.47,48 Nearly all of the mothers in our study used multiple drugs during pregnancy 
so these factors could not be isolated in our patients. Across both categories, only 23 percent 
(seven) of our patients exposed to narcotic pain relievers were exposed to only opiate 
replacement medications; and of these seven patients, six were exposed to at least one of the 
other drugs listed in Table 1. Additionally, over 90 percent of the mothers in our study 
consistently used tobacco, which is known to prolong and increase NAS symptoms.50 Patients 
born at less than 35 weeks’ gestation comprised roughly 20 percent of our NAS patients. Unlike 
large and expensive multidisciplinary initiatives to reduce length of stay, our NICU implemented 
simple and free exercises in addition to the pharmacologic treatment which resulted in an 
average LOS of 21 days. 
 Some papers have shown increases in length of stay as the opioid epidemic unfolds in the 
United States.51 Being in the foothills of Appalachia, the opioid epidemic’s presence here 
outdates, and prevalence here exceeds other regions. In addition to types of drugs used, we 
believe geography may have a role in the length of stay in our patients as well.52  
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 Based on this preliminary study, future research will focus on length of stay for NAS 
patients. In order to maximize the studies to which we can compare our data, we hope to control 
for factors, such as co-occurring drug use, prematurity, and severity as previously mentioned 
papers have done. We recognize the impact post-discharge placement has on length of stay as 
well, and plan to control for babies who were not discharged as soon as they were ready to 
leave.  The study’s small sample size limits the extent to which we can examine differences *
between groups including post-discharge placement circumstances, type of drug exposure, 
pharmacologic treatment received and length of pharmacologic treatment, and more. Additional 
literature regarding nicotine from cigarettes and methadone maintenance therapy (and perhaps, 
all opiates) should be reviewed for the next study because our patients reported tobacco use at 
much higher rates than other studies. This was shown to increase peak NAS scores and alter the 
time course of NAS, which was not considered during data analysis. Because this preliminary 
study excluded all patients who did not stay in Dr. Weinstein’s practice for at least one year or 
until the patient began walking (whichever occurred earliest), a future study of all NAS patients’ 
NICU length of stays will include many more patients. The concept of proprioception’s possible 
role in mediating respiration was previously only considered after data collection. We plan to 
examine the impact of proprioception on respiratory function and assistance in the NICU more 
closely than this study. Reduction in length of stay decreases the social and psychological strain 
on families and their babies; as well as the financial strain on hospitals and patients. Reduced 
length of stay could also indicate decreased pain exposure; pain exposure is associated with 
 One study mentions that some patients spent 1-2 extra days in the NICU while DCS or foster *
care coordinated placement - something we did not consider
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worse developmental outcomes. While still preliminary research, this paper shows promising 
future research directions in neonatology and PM&R.  
Main ideas
• Proprioceptive cross stroking is a free developmental intervention that can be employed by anyone.
• Unlike mechanical and pharmacologic treatments that can have adverse neurodevelopmental 
outcomes and pulmonary development, CS exercises promote self-regulatory soothing and long-term 
development which can reduce hospital length of stay.
• Future research: possible role of antidepressants in reduced opiate/opioid use
• Proprioceptive input can fine-tunes plastic neural connections in the early postnatal stage to reduce 
pain.
• Proprioceptive input may contribute to increased pulmonary function.
• Drug-exposed premature neonates’ NICU stay far exceeds the average premature neonates’ stay, 
which displays the need for further research in this patient population and improved NAS diagnostic 
tools for premature drug-exposed neonates.
• Type of drug exposure can have very different impacts on NAS pathology, course, and timing. This 
should be considered when assessing NICU stay, NICU events and associated treatments, and 
proprioceptive input’s specific role in these patients’ development.
• Drug-Exposed Premature infants begin walking at a later age than their normal premature 
counterparts, indicating a possible compounding effect of adverse developmental conditions.
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